环肽LY146032和万古霉素的抗葡萄球菌活性。
Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.
作者信息
Knapp C C, Washington J A
出版信息
Antimicrob Agents Chemother. 1986 Dec;30(6):938-9. doi: 10.1128/AAC.30.6.938.
Abstract
The inhibitory and bactericidal activities of a novel cyclic peptide antibiotic, LY146032, and vancomycin against oxacillin-susceptible and oxacillin-resistant staphylococci were compared. The MICs for 90% of strains were two- to fourfold higher for vancomycin than for LY146032. MBC/MIC ratios for all strains were less than or equal to 2. In killing rate studies with four strains of staphylococci, there was no detectable growth in the presence of 4X the MIC of either LY146032 or vancomycin after 24 h of incubation.
摘要
比较了新型环肽抗生素LY146032和万古霉素对苯唑西林敏感及苯唑西林耐药葡萄球菌的抑制和杀菌活性。90%菌株的万古霉素MIC比LY146032高2至4倍。所有菌株的MBC/MIC比值均小于或等于2。在对4株葡萄球菌的杀菌率研究中，孵育24小时后，在LY146032或万古霉素4倍MIC浓度下均未检测到细菌生长。
相似文献
1
Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.环肽LY146032和万古霉素的抗葡萄球菌活性。
Antimicrob Agents Chemother. 1986 Dec;30(6):938-9. doi: 10.1128/AAC.30.6.938.
2
In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.LY146032对金黄色葡萄球菌和表皮葡萄球菌的体外活性。
J Antimicrob Chemother. 1987 Oct;20(4):505-11. doi: 10.1093/jac/20.4.505.
3
Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.通过杀菌动力学研究确定LY146032与甲氧西林、头孢唑林、头孢孟多、头孢呋辛、环丙沙星和万古霉素对葡萄球菌的活性比较。
Antimicrob Agents Chemother. 1987 Aug;31(8):1210-5. doi: 10.1128/AAC.31.8.1210.
4
Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.新型脂肽类抗菌药物LY146032（达托霉素）的体外活性比较
Eur J Clin Microbiol. 1987 Feb;6(1):100-3. doi: 10.1007/BF02097211.
5
Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.与万古霉素相比，达托霉素（LY146032）联合或不联合阿米卡星的血清杀菌效价和杀菌率的体外研究。
Antimicrob Agents Chemother. 1989 Oct;33(10):1783-90. doi: 10.1128/AAC.33.10.1783.
6
Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.新型缩肽类抗生素LY146032与万古霉素及其他八种药物对革兰氏阳性菌的体外活性比较
J Antimicrob Chemother. 1987 Aug;20(2):191-6. doi: 10.1093/jac/20.2.191.
7
Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.LY146032和万古霉素对金黄色葡萄球菌的体外杀菌曲线早期阶段。
Antimicrob Agents Chemother. 1988 Apr;32(4):454-7. doi: 10.1128/AAC.32.4.454.
8
In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.新型脂肽抗生素LY146032对革兰氏阳性球菌的体外活性
Antimicrob Agents Chemother. 1987 Feb;31(2):340-2. doi: 10.1128/AAC.31.2.340.
9
Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.替考拉宁、达托霉素、雷莫拉宁、万古霉素和PD127,391对革兰氏阳性球菌血液分离株的体外活性比较
Antimicrob Agents Chemother. 1992 Jul;36(7):1570-2. doi: 10.1128/AAC.36.7.1570.
10
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).亚太地区革兰氏阳性菌分离株的抗菌药敏性以及达托霉素、万古霉素和替考拉宁杀菌活性的体外评估：哨兵计划报告（2003 - 2004年）
Int J Antimicrob Agents. 2007 Aug;30(2):143-9. doi: 10.1016/j.ijantimicag.2007.03.015. Epub 2007 May 24.
引用本文的文献
1
Self-Assembly of Noncanonical Peptides: A New Frontier in Cancer Therapeutics and Beyond.非经典肽的自组装：癌症治疗及其他领域的新前沿
Macromol Biosci. 2025 Aug;25(8):e2500153. doi: 10.1002/mabi.202500153. Epub 2025 Apr 22.
2
Roadmap for antibiotic discovery.抗生素发现路线图。
Nat Microbiol. 2016 May 26;1(6):16083. doi: 10.1038/nmicrobiol.2016.83.
3
In vivo pharmacodynamic activity of daptomycin.达托霉素的体内药效学活性。
Antimicrob Agents Chemother. 2004 Jan;48(1):63-8. doi: 10.1128/AAC.48.1.63-68.2004.
4
Methicillin-resistant staphylococci.耐甲氧西林葡萄球菌
Clin Microbiol Rev. 1988 Apr;1(2):173-86. doi: 10.1128/CMR.1.2.173.
5
Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.脂肽抗生素LY146032的抗菌活性与谱，包括药敏试验建议。
Antimicrob Agents Chemother. 1987 Apr;31(4):625-9. doi: 10.1128/AAC.31.4.625.
6
In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.达托霉素（LY146032）和帕地霉素（U-70,138F）对厌氧革兰氏阳性菌的体外活性。
Antimicrob Agents Chemother. 1988 May;32(5):788-90. doi: 10.1128/AAC.32.5.788.
7
In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide.对新型环脂肽LY146032具有抗性的细菌的体外筛选
Antimicrob Agents Chemother. 1988 Jan;32(1):24-6. doi: 10.1128/AAC.32.1.24.
8
Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.通过杀菌动力学研究确定LY146032与甲氧西林、头孢唑林、头孢孟多、头孢呋辛、环丙沙星和万古霉素对葡萄球菌的活性比较。
Antimicrob Agents Chemother. 1987 Aug;31(8):1210-5. doi: 10.1128/AAC.31.8.1210.
9
Methicillin-resistant staphylococci: detection methods and treatment of infections.耐甲氧西林葡萄球菌：检测方法与感染治疗
Antimicrob Agents Chemother. 1989 Jul;33(7):995-9. doi: 10.1128/AAC.33.7.995.
10
Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin.LY146032与万古霉素治疗慢性实验性金黄色葡萄球菌骨髓炎
Eur J Clin Microbiol Infect Dis. 1989 Jun;8(6):562-3. doi: 10.1007/BF01967482.
本文引用的文献
1
MBCs for Staphylococcus aureus as determined by macrodilution and microdilution techniques.采用常量稀释法和微量稀释法测定的金黄色葡萄球菌的最低杀菌浓度。
Antimicrob Agents Chemother. 1984 Aug;26(2):214-9. doi: 10.1128/AAC.26.2.214.
Zotero 插件